Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 4 | 2012 | 300 | 0.830 |
Why?
|
| Telomerase | 2 | 2012 | 85 | 0.630 |
Why?
|
| Lung Neoplasms | 4 | 2012 | 1172 | 0.560 |
Why?
|
| Mesothelioma | 3 | 2008 | 21 | 0.540 |
Why?
|
| RNA, Messenger | 6 | 2012 | 1663 | 0.440 |
Why?
|
| Pleura | 3 | 2012 | 25 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 756 | 0.400 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2008 | 411 | 0.380 |
Why?
|
| Neoplasm Staging | 3 | 2012 | 799 | 0.320 |
Why?
|
| RNA-Binding Proteins | 3 | 2008 | 215 | 0.300 |
Why?
|
| Venous Thromboembolism | 1 | 2008 | 116 | 0.280 |
Why?
|
| Sepsis | 1 | 2008 | 233 | 0.250 |
Why?
|
| Pregnancy Complications | 1 | 2008 | 286 | 0.250 |
Why?
|
| Reactive Oxygen Species | 2 | 1997 | 499 | 0.250 |
Why?
|
| Epilepsy | 1 | 2008 | 336 | 0.230 |
Why?
|
| Mediastinoscopy | 1 | 2003 | 13 | 0.230 |
Why?
|
| Mediastinum | 1 | 2003 | 39 | 0.220 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 191 | 0.220 |
Why?
|
| Ultrasonography, Interventional | 1 | 2003 | 119 | 0.210 |
Why?
|
| Lymphatic Metastasis | 1 | 2003 | 274 | 0.210 |
Why?
|
| Endosonography | 1 | 2003 | 177 | 0.210 |
Why?
|
| Apoptosis | 3 | 1998 | 1640 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 710 | 0.200 |
Why?
|
| Pleural Neoplasms | 1 | 2000 | 7 | 0.190 |
Why?
|
| Epithelium | 3 | 1998 | 172 | 0.160 |
Why?
|
| Hypertension | 1 | 2008 | 1531 | 0.160 |
Why?
|
| Asbestos, Crocidolite | 1 | 1997 | 1 | 0.160 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1997 | 39 | 0.160 |
Why?
|
| Vascular Diseases | 1 | 2018 | 94 | 0.160 |
Why?
|
| Intensive Care Units | 2 | 2018 | 344 | 0.150 |
Why?
|
| Carcinogens | 1 | 1997 | 86 | 0.150 |
Why?
|
| Ketamine | 1 | 2018 | 57 | 0.150 |
Why?
|
| Adenocarcinoma | 3 | 2005 | 475 | 0.150 |
Why?
|
| Asbestos | 1 | 1996 | 7 | 0.150 |
Why?
|
| Analgesics | 1 | 2018 | 118 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2008 | 235 | 0.140 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 49 | 0.140 |
Why?
|
| Checklist | 1 | 2016 | 76 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 75 | 0.120 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 364 | 0.120 |
Why?
|
| Exercise Test | 1 | 2015 | 242 | 0.120 |
Why?
|
| Therapeutic Irrigation | 1 | 2012 | 63 | 0.110 |
Why?
|
| Walking | 1 | 2015 | 240 | 0.110 |
Why?
|
| Prognosis | 2 | 2012 | 2093 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 207 | 0.100 |
Why?
|
| Mice, SCID | 2 | 2008 | 238 | 0.090 |
Why?
|
| Rabbits | 3 | 2005 | 509 | 0.090 |
Why?
|
| Humans | 13 | 2018 | 68525 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2005 | 624 | 0.080 |
Why?
|
| Glutamate-Cysteine Ligase | 2 | 1998 | 16 | 0.080 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2008 | 34 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 160 | 0.080 |
Why?
|
| Lung | 2 | 2005 | 849 | 0.080 |
Why?
|
| Annexin A5 | 2 | 1997 | 16 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 1997 | 9 | 0.080 |
Why?
|
| DNA Fragmentation | 2 | 1997 | 85 | 0.080 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 1998 | 120 | 0.070 |
Why?
|
| Deferoxamine | 2 | 1997 | 45 | 0.070 |
Why?
|
| Catalase | 2 | 1997 | 85 | 0.070 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2008 | 92 | 0.070 |
Why?
|
| RNA Interference | 1 | 2008 | 266 | 0.070 |
Why?
|
| Doxorubicin | 2 | 1998 | 231 | 0.070 |
Why?
|
| Superoxide Dismutase | 2 | 1997 | 149 | 0.070 |
Why?
|
| Critical Illness | 1 | 2008 | 191 | 0.070 |
Why?
|
| Adult | 4 | 2018 | 21375 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2008 | 1849 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 2005 | 20 | 0.070 |
Why?
|
| RNA, Neoplasm | 2 | 2003 | 76 | 0.070 |
Why?
|
| Phenotype | 1 | 2008 | 946 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2012 | 3702 | 0.060 |
Why?
|
| Epithelial Cells | 2 | 1997 | 431 | 0.060 |
Why?
|
| Animals | 6 | 2008 | 20877 | 0.060 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2005 | 200 | 0.060 |
Why?
|
| Female | 4 | 2018 | 38015 | 0.060 |
Why?
|
| Carcinoma, Large Cell | 1 | 2003 | 6 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 4843 | 0.060 |
Why?
|
| Pregnancy | 1 | 2008 | 2331 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 332 | 0.050 |
Why?
|
| Cell Division | 2 | 2005 | 541 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2003 | 652 | 0.050 |
Why?
|
| Mice | 3 | 2008 | 8472 | 0.050 |
Why?
|
| Male | 4 | 2018 | 37281 | 0.050 |
Why?
|
| Photochemotherapy | 1 | 2000 | 59 | 0.040 |
Why?
|
| Middle Aged | 2 | 2012 | 21119 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 778 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2003 | 1548 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 700 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 1998 | 332 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2000 | 714 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2000 | 212 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2000 | 291 | 0.040 |
Why?
|
| Membrane Lipids | 1 | 1997 | 31 | 0.040 |
Why?
|
| Iron Chelating Agents | 1 | 1997 | 31 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 951 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2550 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2018 | 328 | 0.040 |
Why?
|
| Chelating Agents | 1 | 1996 | 47 | 0.040 |
Why?
|
| Aged | 1 | 2012 | 14842 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1139 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 1997 | 305 | 0.040 |
Why?
|
| Hypoxia | 1 | 1996 | 169 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 239 | 0.030 |
Why?
|
| Pain | 1 | 2018 | 472 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1745 | 0.030 |
Why?
|
| Protein Binding | 1 | 1996 | 1027 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1996 | 659 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 498 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 4655 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 1341 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 1996 | 2673 | 0.020 |
Why?
|
| Risk Factors | 1 | 2000 | 5719 | 0.020 |
Why?
|
| Gene Expression | 2 | 2005 | 770 | 0.020 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 1998 | 24 | 0.020 |
Why?
|
| RNA, Antisense | 1 | 2005 | 25 | 0.020 |
Why?
|
| G2 Phase | 1 | 2005 | 26 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 40 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 7264 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2005 | 98 | 0.020 |
Why?
|
| Bronchi | 1 | 2005 | 59 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 97 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2005 | 295 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 434 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 230 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1174 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 682 | 0.010 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 1998 | 15 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 1998 | 24 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 100 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1998 | 56 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 302 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 852 | 0.010 |
Why?
|
| Base Sequence | 1 | 1998 | 1015 | 0.010 |
Why?
|
| Glutathione | 1 | 1998 | 343 | 0.010 |
Why?
|